Two MMP-2 Promoter Polymorphisms (–790T/G and –735C/T) in Chronic Heart Failure : Clinical Chemistry and Laboratory Medicine Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

249,00 € / $374.00 / £187.00*

Online
ISSN
1437-4331
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

30,00 € / $42.00 / £23.00

Get Access to Full Text

Two MMP-2 Promoter Polymorphisms (–790T/G and –735C/T) in Chronic Heart Failure

Anna Vašků / Monika Goldbergová / Lydie Izakovičová Hollá / Lenka Špinarová / Jindřich Špinar / Jiří Vítovec / Jiří Vácha

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 41, Issue 10, Pages 1299–1303, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2003.197, June 2005

Publication History

Published Online:
2005-06-01

Abstract

Remodelling of extracellular matrix by activated matrix metalloproteinases is considered to contribute to progression of ventricle remodelling during chronic heart failure. The aim of this study was to associate two promoter polymorphisms, -790T/G and -735C/T, in the gene for matrix metalloproteinase (MMP)-2 (gelatinase A) with chronic heart failure (CHF). For this purpose, 164 patients (124 men, 40 women, median age 56 years, range 21-91 years) with CHF (functional class NYHA II-IV, ejection fraction median 25%, cardiothoracic index more than 50%) were compared with 196 control subjects without clinical signs of cardiovascular disease (131 men and 65 women, median age 56 years, range 27-84 years) in -790T/G and -735C/T MMP-2 genotype distributions and allelic frequencies. The genotypes were determined by polymerase chain reaction (PCR) with restriction analyses. A significant increase of the T allele of the -790T/G MMP-2 polymorphism (p = 0.04), as well as of the C allele of the -735C/T MMP-2 gene polymorphism, in patients with CHF was proven (p = 0.04). The heterozygote CT of the 735C/T MMP-2 polymorphism exhibits a 7 times higher odds ratio (OR) for the CHF patients with lower levels of total cholesterol (less than 5 mmol/l), especially for nonhypertensive CHF men (OR = 7.28, 95% confidence interval 1.51-35.03, p = 0.006). Determination of MMP polymorphisms in the regulatory area of the gene could help us to comprehend individual susceptibility of patients with CHF to MMP inhibitors based on known risks of MMP genotypes. Clin Chem Lab Med 2003; 41(10):12991303

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Aldo Clerico, Simona Vittorini, Claudio Passino, and Michele Emdin
Critical Reviews in Clinical Laboratory Sciences, 2009, Volume 46, Number 3, Page 107
[3]
Virgilio Olsen, Luis E. Rohde, Luis Beck-da-Silva, Kátia G. Santos, Andréia Biolo, Nadine Clausell, and Michael Andrades
Canadian Journal of Cardiology, 2014, Volume 30, Number 3, Page 345
[4]
Fabiana Filigheddu
Molecular Diagnosis & Therapy, 2013, Volume 17, Number 4, Page 205
[5]
Priyanka Srivastava, Tasleem A. Lone, Rakesh Kapoor, and Rama Devi Mittal
Archives of Medical Research, 2012, Volume 43, Number 2, Page 117
[6]
Ali Gürkan, Gülnur Emingil, Buket Han Saygan, Gül Atilla, Serhat Çınarcık, Timur Köse, and Afig Berdeli
Archives of Oral Biology, 2008, Volume 53, Number 4, Page 337
[7]
Priyanka Srivastava, Rakesh Kapoor, and Rama D. Mittal
Urologic Oncology: Seminars and Original Investigations, 2013, Volume 31, Number 2, Page 247
[8]
Yihong Hua, Li Song, Naqiong Wu, Gaoqiang Xie, Xiangfeng Lu, Xiaohan Fan, Xianmin Meng, Dongfeng Gu, and Yuejin Yang
Clinica Chimica Acta, 2009, Volume 404, Number 2, Page 119
[9]
Merli Saare, Merit Lamp, Tanel Kaart, Helle Karro, Ülle Kadastik, Andres Metspalu, Maire Peters, and Andres Salumets
Fertility and Sterility, 2010, Volume 94, Number 4, Page 1560
[10]
Ebru Alp, Sevda Menevse, Murat Tulmac, Akin Yilmaz, Ridvan Yalcin, and Atiye Cengel
Genetic Testing and Molecular Biomarkers, 2011, Volume 15, Number 4, Page 193
[11]
Bangwei Cao, Hongli Yang, Howard Ding, Suxia Qi, Lei Gao, Hong Cui, Yue Dai, and Changqing Xu
Clinical Chemical Laboratory Medicine, 2007, Volume 45, Number 3
[12]
Ali Gürkan, Gülnur Emingil, Buket Han Saygan, Gül Atilla, Serhat Çınarcık, Timur Köse, and Afig Berdeli
Journal of Periodontology, 2007, Volume 78, Number 12, Page 2338
[13]
Yihong Hua, Li Song, Naqiong Wu, Xiangfeng Lu, Xianmin Meng, Dongfeng Gu, and Yuejin Yang
The American Journal of the Medical Sciences, 2009, Volume 337, Number 5, Page 344
[14]
Bego??a L??pez, Arantxa Gonz??lez, and Javier D??ez
Current Opinion in Nephrology and Hypertension, 2004, Volume 13, Number 2, Page 197

Comments (0)

Please log in or register to comment.